SkinHealth Systems (SKIN) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
24 Apr, 2026Executive summary
Annual meeting scheduled for June 10, 2026, will be held virtually, allowing shareholders to vote and submit questions online.
Shareholders of record as of April 16, 2026, are eligible to vote on key proposals, including director elections, auditor ratification, and executive compensation.
Proxy materials are distributed primarily online, with paper copies available upon request, and voting can be done via internet, phone, or mail.
Voting matters and shareholder proposals
Shareholders will vote on the election of nine directors, ratification of Deloitte & Touche LLP as independent auditor for 2026, and an advisory say-on-pay vote for executive compensation.
Board recommends voting FOR all director nominees, FOR auditor ratification, and FOR executive compensation.
Shareholder proposals for the 2027 annual meeting must be submitted by December 25, 2026, with additional advance notice requirements outlined in the bylaws.
Board of directors and corporate governance
Board consists of nine nominees with diverse backgrounds in healthcare, finance, operations, and governance.
Majority of directors are independent per Nasdaq and SEC standards; annual board and committee self-evaluations are conducted.
Board committees include Audit, Compensation, and Nominating & Corporate Governance, each with defined charters and independent membership.
Board leadership is separated between Chairman and CEO roles, with regular executive sessions and high attendance at meetings.
Latest events from SkinHealth Systems
- Shareholders to vote on a reverse stock split and possible meeting adjournment on Sept 22, 2026.SKIN
Proxy filing - Shareholders will vote on a reverse stock split to help maintain Nasdaq listing compliance.SKIN
Proxy filing - Q2 2026 sales fell 7.8%, but margins and EBITDA improved amid ongoing market challenges.SKIN
Q2 2026 - Vote sought on a reverse stock split to maintain Nasdaq listing and increase share price.SKIN
Proxy filing - Director elections, auditor ratification, and executive pay were addressed; no questions submitted.SKIN
AGM 2026 - Adjusted EBITDA rose to $8.5M as sales fell and guidance was lowered amid market headwinds.SKIN
Q1 2026 - Margins and profitability improved in 2025, with stable outlook and growth expected in 2027.SKIN
Q4 2025 - Gross margin rebounded to 51.6% in Q3 2024 despite a 19.1% sales decline.SKIN
Q3 2024 - Net sales dropped 22.9% as device sales lagged, prompting a downward revision to 2024 guidance.SKIN
Q2 2024